Psilocybin-assisted therapy for anxiety and depression: implications for euthanasia

Nigel Strauss
Med J Aust 2017; 206 (11): . || doi: 10.5694/mja17.00081
Published online: 19 June 2017

Contemporary research suggests potential benefits of psychedelic drugs in treatment-resistant depression and terminally ill patients

Despite their stigmatisation, psychedelic drugs are once again being clinically researched in Europe and North America. This long-awaited renaissance is showing very promising results and, unlike the pioneering research that occurred before these drugs were outlawed over 30 years ago, the current methodology is rigorous and of a very high standard.

  • Nigel Strauss

  • Millswyn Clinic, Melbourne, VIC



I thank Martin Williams for his assistance in the preparation and revision of this manuscript.

Competing interests:

No relevant disclosures.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.